Healthcare stocks have emerged as the strongest performers on the Australian Securities Exchange (ASX) in recent weeks, reversing a period of underperformance that lasted up to two years for some major players. The ASX healthcare index has surged by more than 20 percent in the past month, significantly outpacing the ASX 200, which has gained around 4 percent over the year to date.
The sector’s resurgence follows a challenging period marked by company-specific setbacks and broader market headwinds. Among the most notable recoveries is CSL, Australia’s blood products giant, which experienced a precipitous share price decline from around AUD 220 to as low as AUD 90 in June of last year. After a 44 percent rally this month alone, CSL shares have rebounded to about AUD 172. The company’s troubles partly stemmed from its costly 2021 acquisition of Swiss biotech firm Vifor, valued at approximately US$11 billion, which required a substantial write-down of about 50 percent of its value. Investors’ renewed confidence in CSL has been tempered by ongoing uncertainty around the appointment of a permanent new CEO.
Other key healthcare stocks have also posted gains. Bionic ear manufacturer Cochlear and sleep device company ResMed have registered double-digit increases in share prices in the last month, reflecting stronger-than-expected earnings and improved market sentiment. Hospital operator Ramsay Healthcare, after facing significant pressures related to cost management and overseas operations, has similarly shown signs of recovery with earnings surpassing forecasts.
Industry analysts attribute the sector’s turnaround to several factors. Solid financial results released during recent earnings season have helped dispel lingering investor concerns. Additionally, the healthcare sector is viewed as a defensive and reliable source of revenue, offering recurring earnings and regulated price adjustments, characteristics that appeal to investors amid broader economic uncertainties. Furthermore, some market participants are seeking investments less exposed to artificial intelligence-driven disruptions, intensifying demand for healthcare shares.
Globally, healthcare has faced challenges, particularly in the United States, where policy uncertainties—such as efforts to limit private health insurance introduced during the Trump administration and endorsed by health officials like Robert F. Kennedy Jr—have contributed to investor caution. However, Australian healthcare companies have benefitted from structural factors, notably an aging population, which underpins sustained demand for healthcare services and innovation.
Despite the rapid rebound, some caution remains. While consensus price targets for CSL hover around AUD 162, questions linger regarding the sustainability of the recovery and the impact of management changes. Nonetheless, the sector’s performance suggests renewed investor confidence and highlights healthcare’s resilience as a growth area distinct from the volatile technology-driven segments of the market.